MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension as ...

Core Insights - Liquidia Corporation announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, with a total of approximately $148.3 million in sales for the year and $90.1 million in the fourth quarter [1][5][6] - The company experienced a 74% quarter-over-quarter growth in net product sales, indicating strong market demand and physician confidence in YUTREPIA [6] - Liquidia plans to report fully audited financial results for the year ended December 31, 2025, in February 2026 [1] Financial Highlights - Estimated net product sales for YUTREPIA were approximately $90.1 million in Q4 2025 and $148.3 million for the full year [5][6] - Generated over $30 million in positive cash flow during Q4 2025 [5][6] - Cash and cash equivalents stood at approximately $190.7 million as of December 31, 2025 [6] Commercial Launch and Adoption - YUTREPIA was successfully launched for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The company received more than 2,800 unique patient prescriptions since the launch in June 2025, with over 2,200 patients starting treatment [5][6] - An 85% conversion rate from prescription to patient start was maintained for prescriptions received through the end of November 2025 [6] Clinical Pipeline and Future Plans - Liquidia aims to advance clinical programs for YUTREPIA and L606, targeting additional indications such as idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) [3][5] - The company is initiating multiple open-label studies to evaluate YUTREPIA's efficacy in various patient groups, including those with inadequate responses to existing treatments [5][6] - Liquidia is also enrolling patients in the global pivotal Phase III study for L606, an investigational extended-release formulation of treprostinil [7]

Core Viewpoint - Liquidia Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on innovative therapies for respiratory and vascular diseases [1]. Group 1: Company Overview - Liquidia Corporation is a biopharmaceutical company dedicated to revolutionizing care for patients with challenging respiratory and vascular diseases through innovative therapies and its proprietary PRINTTechnology [3]. - The company’s first approved product is YUTREPIA™ (treprostinil) inhalation powder, which is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3]. - Liquidia is also developing L606, an investigational extended-release formulation of treprostinil, which is administered twice daily using a next-generation nebulizer [3]. - Additionally, the company markets generic Treprostinil Injection for the treatment of PAH [3]. Group 2: Event Information - Dr. Roger Jeffs, the CEO of Liquidia, will present at the conference starting at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) [1]. - A live, audio-only webcast of the presentation will be available on the "Investors" page of Liquidia's website and will be archived for at least 30 days [2].

Core Insights - Liquidia Corporation is focused on revolutionizing care for patients with respiratory and vascular diseases through innovative therapies and proprietary technology [2] Company Updates - Liquidia's executive leadership team will provide business updates during fireside chats at two investor conferences in November [1] - The conferences include the 2025 UBS Global Healthcare Conference on November 10 and the Jefferies London Healthcare Conference on November 18 [3] Product Information - Liquidia's first approved product is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The company is developing L606, a sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [2] - Liquidia also markets generic Treprostinil Injection for the treatment of PAH [2]

Core Viewpoint - Liquidia Corporation is set to report its third quarter 2025 financial results on November 3, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Group 1: Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3]. Group 2: Webcast Information - The upcoming webcast will be available on Liquidia's website and will be archived for one year [2].

Core Insights - Liquidia Corporation is hosting its first Research & Development Day on October 28, 2025, in New York City, focusing on innovative therapies for rare cardiopulmonary diseases [1][3] Group 1: Event Details - The R&D Day will feature presentations from Liquidia's management and key opinion leaders in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The agenda will include updates on L606, an investigational sustained-release formulation, and the flagship product YUTREPIA™ [2][3] - The event is intended for institutional investors and sell-side analysts, with options for in-person attendance and live webcasting [3][4] Group 2: Product Information - L606 is a twice-daily administered investigational formulation of treprostinil, utilizing a proprietary liposomal formulation for controlled drug release [5] - YUTREPIA is an inhaled dry-powder formulation of treprostinil designed for improved exercise ability in patients with PAH and PH-ILD, developed using Liquidia's PRINT® technology [6][7] - Liquidia is also marketing Treprostinil Injection, a fully substitutable generic of Remodulin for PAH treatment [7]

Core Insights - Liquidia Corporation will provide a business update during a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 3:45 p.m. ET in Boston [1] - Investors and interested parties can access a webcast of the presentation on Liquidia's website, with an archived version available for at least 30 days post-event [2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's current focus includes the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT Technology [3] - Liquidia's first approved product is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]

Core Insights - Liquidia Corporation reported a second-quarter loss of 49 cents, which was worse than the consensus estimate of a loss of 43 cents, but sales reached $8.84 million, significantly exceeding the consensus of $3.86 million [1][2] Financial Performance - The company experienced a second-quarter loss of 49 cents per share, missing the expected loss of 43 cents [1] - Sales for the quarter were reported at $8.84 million, surpassing the consensus estimate of $3.86 million [1] Product Development and Market Response - Liquidia analyzed interim data from the ASCENT study, which involved 54 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The FDA approved and launched YUTREPIA™ (treprostinil) inhalation powder, with over 350 physicians prescribing it within 11 weeks of approval, leading to more than 900 unique patient prescriptions and over 550 patient starts [3] Analyst Ratings and Price Targets - Wells Fargo analyst Tiago Fauth maintained an Overweight rating on Liquidia and raised the price target from $25 to $31 [6] - Raymond James analyst Ryan Deschner maintained a Strong Buy rating and increased the price target from $33 to $41 [6]

Core Viewpoint - Liquidia Corporation reported strong early commercial performance and clinical evidence for its newly approved product YUTREPIA, indicating significant market demand and potential for growth in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2][3][5] Company Highlights - The FDA approved YUTREPIA on May 23, 2025, and it was commercially launched in June 2025, with over 900 unique patient prescriptions and more than 550 patient starts recorded within 11 weeks post-launch [6][7] - The initial demand for YUTREPIA has exceeded expectations, with 75% of prescriptions converting to treatment starts in the first six weeks [7] - Liquidia has signed a lease for approximately 70,000 square feet of additional manufacturing space, targeted for occupancy in 2026, to support continued growth [7] - The company received $50 million under its financing agreement with Healthcare Royalty following the first commercial sale of YUTREPIA [7] Clinical Evidence - The ongoing ASCENT study has shown positive interim data, with median improvements in six-minute walk distance of 21.5 meters at Week 8 and 31.5 meters at Week 16, reinforcing YUTREPIA's tolerability and efficacy profile [4][8] - The study fully enrolled 54 patients, with no discontinuations due to drug-related adverse events, indicating a favorable safety profile [4][8] Financial Performance - As of June 30, 2025, Liquidia reported cash and cash equivalents of $173.4 million, a slight decrease from $176.5 million at the end of 2024 [9][27] - Product revenue for the second quarter of 2025 was $6.5 million, marking the first revenue recognition following YUTREPIA's approval [9][28] - Service revenue decreased to $2.3 million from $3.7 million in the same period last year, primarily due to unfavorable gross-to-net returns [10][28] - Research and development expenses decreased by 36% to $6.0 million, reflecting a shift towards commercialization activities [12][28] - Selling, general and administrative expenses increased by 95% to $38.8 million, driven by higher personnel costs and legal fees related to ongoing litigation [13][28] - The net loss for the second quarter was $41.6 million, or $0.49 per share, compared to a net loss of $28.7 million, or $0.38 per share, in the prior year [14][28]

Core Viewpoint - Liquidia Corporation is set to report its second quarter 2025 financial results on August 12, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is engaged in the development and commercialization of products targeting pulmonary hypertension, utilizing its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is designed for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily using a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3].